⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29210333 | 0.97 | — | — | |
| SCHEMBL13538731 | 0.73 | CA5A (0.33) | — | |
| SCHEMBL9289667 | 0.73 | CA5A (0.33) | — | |
| SCHEMBL23501717 | 0.71 | CA5A (0.31) | — | |
| Sulfuric Acid SCHEMBL9751462 | 0.71 | GABRR1 (0.46) | — | |
| SCHEMBL1695401 | 0.71 | CA5A (0.31) | — | |
| SCHEMBL270856 | 0.71 | — | — | |
| SCHEMBL14058748 | 0.71 | CA5A (0.31) | — | |
| SCHEMBL5158836 | 0.71 | LMNA (0.38) | — | |
| SCHEMBL28680211 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022269026-A1 | TREATING ACETAMINOPHEN OVERDOSE | FORSCHUNGSGESELLSCHAFT FÜR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ E. V. (DE) | 2022-12-29 | — | — | WO | claimed |
| EP-0910379-B1 | PLASTER FOR THE TRANSDERMAL APPLICATION OF PERGOLIDE | HEXAL AG (DE) | 2003-04-23 | — | — | EP | claimed |
| US-6036973-A | Therapy for neurological diseases | ALZA CORPORATION (US) | 2000-03-14 | — | — | US | claimed |
| US-12616685-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates | CORCEPT THERAPEUTICS INCORPORATED (US) | 2026-05-05 | — | — | US | disclosed |
| US-12589094-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 | CORCEPT THERAPEUTICS INCORPORATED (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250199015-A1 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | INCYCLIX BIO, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-120131508-A | Composition with effects of controlling oil, removing acnes and repairing barrier and application thereof | 北京植物医生生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4540256-A2 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | Incyclix Bio, LLC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119403808-A | Cyclin-dependent kinase 2 inhibitors for medical treatment | 因西克利克斯生物有限责任公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240261277-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 | Concept Therapeutics Incorporated (US) | 2024-08-08 | — | — | US | disclosed |
| US-11944617-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-04-02 | — | — | US | disclosed |
| US-6034117-A | Methods of treating and diagnosing sleep disordered breathing and means for carrying out the method | PHARMAPNEA AB (SE) | 2000-03-07 | — | — | US | disclosed |
| EP-0923370-A2 | METHOD OF TREATING AND DIAGNOSING SLEEP DISORDERED BREATHING AND MEANS FOR CARRYING OUT THE METHOD | A+ Science Invest AB (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997022339-A1 | METHOD OF TREATING AND DIAGNOSING SLEEP DISORDERED BREATHING AND MEANS FOR CARRYING OUT THE METHOD | HEDNER JAN (SE) | 1997-06-26 | — | — | WO | disclosed |
| US-5466696-A | Mixtures for treatment of alzheimer's disease | WARNER LAMBERT COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0659082-A1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5422350-A | Alzheimer's disease | WARNER-LAMBERT COMPANY (US) | 1995-06-06 | — | — | US | disclosed |
| WO-1994005296-A2 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0272588-B1 | ACETYLENE DIUREA DERIVATIVES AND THEIR USE IN STABILIZING SYNTHETIC RESINS | BASF Aktiengesellschaft (DE) | 1992-10-14 | — | — | EP | disclosed |
| EP-0272588-A1 | Acetylene diurea derivatives and their use in stabilizing synthetic resins | BASF Aktiengesellschaft (DE) | 1988-06-29 | — | — | EP | disclosed |